The Economist Events' War on Cancer 2016

LONDON, November 30, 2016 /PRNewswire/ --

Exploring solutions to the mismatch in progress and delivery in cancer care 

Tweet your questions ahead of the event via @EconomistEvents #WaronCancer 

The Economist Events' second annual War on Cancer 2016 will bring together over 150 global leaders in oncology to explore solutions to the mismatch in progress and delivery in cancer care across Europe. The forum will discuss innovative approaches to cancer prevention and treatment, solutions to overcome shortcomings in delivery and examples of best practices and opportunities for cross-sectoral collaboration.

The forum will be held on Tuesday, December 6^th 2016 at the Marriott Grosvenor Square, London, from 8:00am to 5:40pm.

Mary-Jane Elliott, Managing Partner at Consilium Strategic Communications, the Official PR Agency for The Economist Events' War on Cancer forum, commented: "Healthcare systems around the world are facing a range of challenges, many of which have the potential to directly impact how cancer will be treated in the future. This forum will bring together leading oncologists and other key stakeholders to discuss how we can ensure health systems remain sustainable in order to deliver promising new technologies and treatments in the fight against cancer. Consilium is very proud to support the event again for this, its second year.  We are looking forward to the forum, the panels and the lively discussions it will provoke."

Innovative approaches to cancer treatment, prevention and care are emerging at an unprecedented rate. However, the policies and systems in place to deliver these advancements to people are lagging behind. Currently in the UK to get a new medicine from the research lab to patients it takes an average of 10 years and £1 billion. Whether we are fighting cancer with novel therapies or adopting the latest preventative guidance, we must ensure that our systems are up to the task of delivering progress. How do we scale the knowledge and capability in oncology that we already have and prepare for what's coming?

Key speakers at the summit include: 

• Matti Aapro, Board Member, European Cancer Organisation
• Cary Adams, Chief Executive Officer, Union for International Cancer Control
• Tit Albreht, Coordinator, Cancer Control Joint Action (CanCon); Head, National Institute of Public Health of Slovenia
• Kathi Apostolidis, Vice-president, European Cancer Patient Coalition (ECPC); President of Executive Committee, Hellenic Cancer Federation - ELL.O.K
• Frauke Becker, Research Associate, Institute of Health and Society, Newcastle University
• John Bell, Regius Professor of Medicine, University of Oxford; Chairman, Office for Strategic Coordination of Health Research (OSCHR)
• Jurgi Camblong, Chief Executive Officer and Co-founder, Sophia Genetics
• Josep Figueras, Director, European Observatory on Health Systems and Policies; Head, World Health Organization European Centre on Health Policy
• George Freeman, Member of Parliament for Mid Norfolk and Chair, Prime Minister's Policy Board
• David Khayat, Head of the Department of Oncology, Pitié-Salpêtrière Hospital and Professor of Oncology, University Pierre and Marie Curie
• Bryony Kimmings, Creator of the musical 'A Pacifist's Guide to the War on Cancer'
• Jane Maher, Chief Medical Officer, Macmillan Cancer Support
• Lydia Makaroff, Director, European Cancer Patient Coalition
• Mahiben Maruthappu, Co-founder, NHS Innovation Accelerator
• Maya Martinez - Davis, Senior Vice-president, Global Head of Oncology Franchise, Merck KGaA
• Vivek Muthu, Chair, Economist Intelligence Unit Healthcare
• Luca Pani, CHMP-SAWP, Member European Medicines Agency (EMA); Department of Psychiatry and Behavioral Sciences, University of Miami
• Annie Pannelay, Healthcare Principal, Economist Intelligence Unit
• Terje Peetso, Policy Officer, Directorate-General Communications Networks, Content and Technology, European Commission
• Andreas Penk, Regional President Oncology, International Developed Markets, Pfizer
• Jem Rashbass, National Director for Disease Registration, Public Health England
• Gunnar Saeter, Professor and Head of Institute, Institute for Cancer Research - Olso University Hospital
• Katherine Smith, Reader- Global Public Health Unit, University of Edinburgh
• Zhen Su, Vice-president, US Oncology Medical Affairs, EMD Serono
• Richard Sullivan, Professor of Cancer and Global Health, King's College London; Director, Institute of Cancer Policy
• Frans van Houten, Chief Executive and Chairman, Philips
• Paul Workman, Chief Executive Officer and President, The Institute of Cancer Research London; Harrap Professor of Pharmacology and Therapeutics

For more information and to view the full programme please visit: http://www.economist.com/events-conferences/emea/war-cancer#ec-event-overview

Follow the War on Cancer summit via @EconomistEvents #WaronCancer on Twitter to get the latest updates, submit your questions, and join in with discussions on the day.

Want more from The Economist Events? 

Join us on Twitter: @EconomistEvents

About The Economist Events 

The Economist Events' philosophy is to tackle issues with a forward-looking, uniquely global perspective. We aim to create events for the intellectually curious: people who enjoy ideas and who are passionate about the issues that define our world.

Attend our events: http://www.economist.com/events-conferences/emea

Founding sponsor: Bristol-Myers Squibb 

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are committed to changing survival expectations in hard-to-treat cancers and the way patients live with cancer through our pioneering, comprehensive Immuno-Oncology portfolio and clinical program as well as research collaborations with academia and biotech companies.

Founding sponsor: Merck 

Merck discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas including oncology and immuno-oncology; supporting patients with cancer. Merck has a robust pipeline of potential therapies in oncology, immuno-oncology and immunology.

Gold sponsor: Pfizer Oncology 

Pfizer Oncology is focused on helping to redefine life with cancer. By maximizing our internal scientific resources and collaborating with other companies, government and academic institutions, we bring together the brightest and most enterprising minds to take on the toughest cancers, helping speed breakthrough treatments to patients around the world.

Silver Sponsor: Novartis 

Novartis Oncology is a global leader in providing a broad range of innovative therapies to help improve the lives of cancer patients.

Silver Sponsor: Varian Medical Systems 

Global manufacturer of medical devices and software for treating cancer with radiotherapy, radiosurgery, proton therapy and brachytherapy.

About Consilium Strategic Communications  

Consilium Strategic Communications is a global leader in providing trusted, healthcare-focused strategic IR and financial PR counsel to corporations, Boards, senior decision makers and executives. From offices in Europe and USA, Consilium Strategic Communications' senior team provides cross-border comprehensive financial and corporate healthcare communications advice to some of the world's most prominent corporations around-the-clock. For more information, please visit our website at http://www.consilium-comms.com

Press enquiries

For further information on event registration or to request interviews with any of the speakers at War on Cancer 2016 conference, please contact Consilium Strategic Communications, Official Press Office for The Economist Healthcare Events:

Lindsey Neville
Email: waroncancer2016@consilium-comms.com
Tel: +44 (0)20-3709-5700

For general queries or further information about the event please call +44(0)207-576-8118 or e-mail emeaevents@economist.com